Goldman Sachs maintained a Buy on Regeneron Pharma (NASDAQ: REGN) and trimmed its price target to $353.00 (from $355.00). 2013-2016 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE